AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed significant improvement as a first line treatment of metastatic breast cancer ...

AstraZeneca, said: "The clinically meaningful improvement in pathologic complete response and the safety data seen in DESTINY-Breast11 highlight the potential of ENHERTU to challenge the current ...

AstraZeneca’s oncology R&D chief Susan Galbraith, Ph.D., characterized Enhertu’s performance in HER2-low and HER2-ultralow subgroups as “exciting.” And Daiichi Sankyo’s head of global ...

2,3 Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “The clinically meaningful improvement in pathologic complete response and the safety data seen in ...

Enhertu is an antibody drug conjugate (ADC) that was discovered by Daiichi Sankyo and is being further developed and commercialized under a partnership with AstraZeneca. The antibody component of ...

AstraZeneca and Daiichi Sankyo are preparing regulatory filings that could make their HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the ...

Daiichi Sankyo and AstraZeneca’s ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer ...